| Unique ID issued by UMIN | UMIN000063663 |
|---|---|
| Receipt number | R000072859 |
| Scientific Title | Establishment of a non-invasive remote screening system for lower extremity artery disease (LEAD) in patients on dialysis: a diagnostic accuracy study of multimodal remote assessment complementing the limitations of the ankle-brachial index (ABI) |
| Date of disclosure of the study information | 2026/11/17 |
| Last modified on | 2026/11/17 09:48:52 |
Feasibility of remote detection of leg artery disease by vascular specialists in people on dialysis, using foot photographs and simple test results collected at dialysis facilities
A Study on Remote LEAD Screening for Dialysis Patients
Establishment of a non-invasive remote screening system for lower extremity artery disease (LEAD) in patients on dialysis: a diagnostic accuracy study of multimodal remote assessment complementing the limitations of the ankle-brachial index (ABI)
A Study on Remote LEAD Screening for Dialysis Patients
| Japan |
Lower extremity artery disease (LEAD) in patients on maintenance dialysis
| Nephrology | Vascular surgery |
Others
NO
To evaluate, in routine dialysis settings, the feasibility of a remote screening system (Steplife) in which vascular specialists asynchronously assess simple data collected by non-specialist staff at dialysis facilities (photographs of the feet, arterial pulse palpation, photographs of Doppler waveforms, and symptoms).
Specifically, to determine the proportion of patients for whom the specialists could reach a remote judgement (judgeability rate), the proportion judged positive for suspected LEAD or ischemia (remote positive rate), and the acquisition rate of each data item collected at the facilities. In addition, disease status is assigned by a predefined composite reference standard, and sensitivity and specificity are calculated as secondary outcomes.
Others
Feasibility and diagnostic accuracy
Exploratory
Pragmatic
Not applicable
Positive and Negative Predictive Values for Telemedical Screening: The proportion of cases among all registered cases that received a final positive or negative determination (point estimate and 95% confidence interval). The evaluation period spans from data entry at the case-registering institution (baseline) until the completion of the telemedical evaluation by a specialist (cases for which a final determination is not confirmed within 14 days of the telemedical evaluation request being entered into the system are classified as "pending").
1. Remote positive rate and referral rate (proportion of patients referred to a specialist institution by the attending physician within 90 days of the index date, i.e., the date the data for judgement were obtained)
2. Acquisition rate of each data item (foot photographs, arterial palpation, Doppler waveform images)
3. Inter-rater agreement between the two evaluators (kappa coefficient)
4. Reasons for indeterminate judgements
5. Agreement between facility staff and evaluators in Doppler waveform classification (weighted kappa coefficient)
6. Time to judgement (from case submission to final judgement)
7. Consent rate
8. Sensitivity and specificity against the composite reference standard (established diagnosis at the index date, results of examinations at specialist institutions within 90 days, and clinical course over 90 days)
9. Number and proportion of additional detections among patients with a negative ABI (negative defined as ABI >0.7 and, separately, as ABI >=0.9)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
NO
NO
Institution is not considered as adjustment factor.
NO
No need to know
1
Diagnosis
| Other |
Staff at the dialysis facility take photographs of the feet, palpate the dorsalis pedis and posterior tibial arteries, record and briefly classify Doppler waveforms with a portable Doppler device, and ask about symptoms; these data are entered into the remote screening system (Steplife). Two vascular specialists who are not involved in the patient's care independently review the data and judge whether LEAD or ischemia is suspected (positive, negative, or indeterminate); if the two disagree, an adjudicator (another vascular specialist) makes the final judgement. The evaluators are blinded to the results of reference standard examinations, ABI values, and subsequent outcomes. The judgement is returned to the attending physician, who decides on referral as part of routine care. Data are collected once at baseline, and the clinical course over the following 90 days is collected from medical records. No examination corresponding to the reference standard (contrast CT, angiography, SPP, TBI) is newly performed for research purposes.
| 18 | years-old | <= |
| Not applicable |
Male and Female
1. Patients on maintenance dialysis aged 18 years or older at the time of consent who attend a participating facility during the enrollment period
2. Patients who have given written informed consent to participate in this study
1. Patients in a serious general condition whom the principal investigator at the participating site considers difficult to evaluate in this study
2. Patients for whom the principal investigator at the participating site considers it difficult to give consent themselves because of cognitive decline or other reasons
90
| 1st name | Shinya |
| Middle name | |
| Last name | Takase |
Fukushima Medical University, School of Medicine
Department of Advanced Integrated Angiology
9601295
1 Hikarigaoka, Fukushima City, Fukushima
0245471281
s-takase@fmu.ac.jp
| 1st name | Shinya |
| Middle name | |
| Last name | Takase |
Fukushima Medical University, School of Medicine
Department of Advanced Integrated Angiology
9601295
1 Hikarigaoka, Fukushima City, Fukushima
0245471281
s-takase@fmu.ac.jp
Fukushima Medical University, School of Medicine
SECOND HEART Inc.
Profit organization
JAPAN
SECOND HEART Inc.
Fukushima Prefecture, FY2026 Innovation Creation Support Subsidy (Fukushima Tech Create Acceleration Program), awarded to SECOND HEART Inc. and used for the costs of this study
Fukushima Medical University Ethics Committee
1 Hikarigaoka, Fukushima-city, Fukushima 9601295 JAPAN
024-547-1825
fmurec@fmu.ac.jp
YES
REC2026-117
Fukushima Medical University Ethics Committee
福島県立医科大学(福島県)、福島第一病院(福島県)、常磐病院(福島県)、いわき泌尿器科(福島県)、ニュータウン腎・内科クリニック(福島県)、大町病院(福島県)、南相馬市立総合病院(福島県)、相馬中央病院(福島県)、公立相馬総合病院(福島県)
| 2026 | Year | 11 | Month | 17 | Day |
Unpublished
Preinitiation
| 2026 | Year | 09 | Month | 25 | Day |
| 2026 | Year | 11 | Month | 16 | Day |
| 2026 | Year | 11 | Month | 20 | Day |
| 2027 | Year | 03 | Month | 31 | Day |
| 2027 | Year | 03 | Month | 31 | Day |
| 2027 | Year | 03 | Month | 31 | Day |
| 2027 | Year | 06 | Month | 30 | Day |
This is a multicenter prospective cohort study. Because the remote screening judgement is generated for this study and returned to the attending physician to inform the referral decision, the study is handled as research involving intervention under the Ethical Guidelines for Life Science and Medical Research Involving Human Subjects in Japan. It involves no invasive procedures. Results will be reported with reference to STARD 2015.
| 2026 | Year | 11 | Month | 17 | Day |
| 2026 | Year | 11 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072859